Skip to content

Effect of duloxetine on perioperative stress response and accelerated rehabilitation of total hip arthroplasty

Effect of duloxetine on perioperative stress response and accelerated rehabilitation of total hip arthroplasty: a prospective, double-blind randomized controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100051099
Enrollment
Unknown
Registered
2021-09-13
Start date
2021-09-30
Completion date
Unknown
Last updated
2022-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total hip arthroplasty

Interventions

Group B:Blank control

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients who need primary unilateral THA surgery due to severe osteoarthritis of the hip; 2. Age is 18~75 years old; 3. The preoperative American Society of Anesthesiologists (ASA) classification (anesthesia risk assessment) was grade I-III.

Exclusion criteria

Exclusion criteria: 1. Patients with heart, lung and other important organ failure; 2. Abnormal liver and kidney function (ALT, AST> 1.5 times the normal value, blood BUN> -8.3 mmol/L, blood Scr> 115 umol/L); 3. Diabetic patients with poor control of blood sugar levels, who are judged by the researchers to be at risk of infection; 4. Combined with disturbance of consciousness or mental illness; 5. Have a history of hip open surgery; 6. Neuromuscular dysfunction affects lower extremity function; 7. Patients with severe coagulation disorders; 8. Combined with severe medical or surgical diseases or weak constitution, unable to tolerate surgery; 9. Severe osteoporosis, metabolic bone disease, radiation bone disease, and tumor around the hip joint; 10. Active infection foci in the body (systemic or local infection lesions); 11. Clearly diagnosed mental diseases and endocrine system diseases; 12. Users of hormone drugs and immunosuppressants; 13. Women in family planning, lactation and pregnancy during the entire clinical research period; 14. Those who have participated in other clinical trials within 3 months; 15. The investigator believes that it is not suitable to participate in this clinical trial due to other reasons; 16. Those who are allergic to or have contraindications to the drugs used in this study; 17. History of alcoholism, opioid addiction; 18. Language barriers and those who cannot complete the scale assessment.

Design outcomes

Primary

MeasureTime frame
Blood stress index;Hamilton Anxiety Scale, HAMA;

Secondary

MeasureTime frame
Hamilton Depression Scale, HAMD;Central Sensitivity Questionnaire;Postoperative morphine consumption;Harris hip score;Pittsburgh sleep quality index,PSQI;quality of life scale;range of motion;VAS score;Length of stay;

Countries

China

Contacts

Public ContactKang Pengde

West China Hospital of Sichuan University

kangpd@163.com+86 18980601953

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026